Page last updated: 2024-08-07 18:27:58
Bile salt export pump
A bile salt export pump that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95342]
Synonyms
EC 7.6.2.-;
ATP-binding cassette sub-family B member 11
Research
Bioassay Publications (11)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
Compounds (957)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| adenine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| quinacrine | Homo sapiens (human) | IC50 | 101.1000 | 1 | 1 |
| betaine | Homo sapiens (human) | IC50 | 1,000.0000 | 3 | 3 |
| carnitine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| coumarin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| salicylic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| bupropion | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| guaiacol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| histamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| melatonin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| acetanilide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pyrazinamide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pyridoxine | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| 1-(3-chlorophenyl)piperazine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| enprofylline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| oxyquinoline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| tacrine | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| acetaminophen | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| acetarsol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| acetazolamide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| ethacridine | Homo sapiens (human) | IC50 | 43.4800 | 1 | 1 |
| 4-(acetylamino)benzeneacetic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| adiphenine | Homo sapiens (human) | IC50 | 158.4000 | 1 | 1 |
| aklomide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| albendazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| albuterol | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| alprenolol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| altretamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| diatrizoic acid | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| aminoglutethimide | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| p-aminohippuric acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| theophylline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| amiodarone | Homo sapiens (human) | IC50 | 26.0000 | 3 | 3 |
| dan 2163 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| amitriptyline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| amlexanox | Homo sapiens (human) | IC50 | 104.0000 | 1 | 1 |
| amlodipine | Homo sapiens (human) | IC50 | 74.5000 | 2 | 2 |
| amodiaquine | Homo sapiens (human) | IC50 | 77.7600 | 1 | 1 |
| amoxapine | Homo sapiens (human) | IC50 | 181.5500 | 2 | 2 |
| amprolium | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| amsacrine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| anastrozole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| antazoline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| anthralin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| antipyrine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | Homo sapiens (human) | IC50 | 390.9000 | 1 | 1 |
| arecoline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| aspirin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| astemizole | Homo sapiens (human) | IC50 | 34.4000 | 2 | 2 |
| atenolol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| azathioprine | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| baclofen | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bendroflumethiazide | Homo sapiens (human) | IC50 | 69.5500 | 1 | 1 |
| benserazide | Homo sapiens (human) | IC50 | 116.6000 | 1 | 1 |
| benzbromarone | Homo sapiens (human) | IC50 | 16.9667 | 3 | 3 |
| benzocaine | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| benzothiazide | Homo sapiens (human) | IC50 | 57.4300 | 1 | 1 |
| bepridil | Homo sapiens (human) | IC50 | 16.4600 | 1 | 1 |
| betaxolol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| bethanechol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| bicalutamide | Homo sapiens (human) | IC50 | 54.4500 | 2 | 2 |
| bay h 4502 | Homo sapiens (human) | IC50 | 27.1000 | 1 | 1 |
| bisacodyl | Homo sapiens (human) | IC50 | 94.6800 | 2 | 2 |
| bretylium | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| bromhexine | Homo sapiens (human) | IC50 | 20.2700 | 1 | 1 |
| bromopride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| seratrodast | Homo sapiens (human) | IC50 | 14.3100 | 1 | 1 |
| bronopol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bumetanide | Homo sapiens (human) | IC50 | 264.8000 | 3 | 3 |
| buspirone | Homo sapiens (human) | IC50 | 88.0433 | 3 | 3 |
| busulfan | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| butacaine | Homo sapiens (human) | IC50 | 487.5000 | 1 | 1 |
| butamben | Homo sapiens (human) | IC50 | 181.1000 | 1 | 1 |
| caffeine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| verapamil | Homo sapiens (human) | IC50 | 131.5000 | 4 | 4 |
| carbamylcholine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| carbamazepine | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| carbinoxamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| carmustine | Homo sapiens (human) | IC50 | 410.0700 | 3 | 3 |
| carprofen | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| carteolol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| carvedilol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| celecoxib | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| chlorambucil | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| chlordiazepoxide | Homo sapiens (human) | IC50 | 34.5500 | 2 | 2 |
| chloroquine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| chloroxylenol | Homo sapiens (human) | IC50 | 129.9000 | 1 | 1 |
| chlorpheniramine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| chlorpromazine | Homo sapiens (human) | IC50 | 95.1617 | 6 | 6 |
| chlorpropamide | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| chlorthalidone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| chlorzoxazone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cifenline | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ciclopirox | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ciglitazone | Homo sapiens (human) | IC50 | 37.8000 | 2 | 2 |
| cilostazol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cimetidine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| aricine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ciprofibrate | Homo sapiens (human) | IC50 | 280.2333 | 3 | 3 |
| ciprofloxacin | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| citalopram | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| clioquinol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| clobazam | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| clofazimine | Homo sapiens (human) | IC50 | 16.8500 | 4 | 4 |
| clofibrate | Homo sapiens (human) | IC50 | 65.5000 | 2 | 2 |
| clomiphene | Homo sapiens (human) | IC50 | 71.5000 | 2 | 2 |
| clomipramine | Homo sapiens (human) | IC50 | 101.8000 | 3 | 3 |
| 4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| clotrimazole | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| cloxyquin | Homo sapiens (human) | IC50 | 356.7000 | 1 | 1 |
| cromolyn | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| cyclandelate | Homo sapiens (human) | IC50 | 15.0300 | 1 | 1 |
| cyclobenzaprine | Homo sapiens (human) | IC50 | 107.4000 | 1 | 1 |
| dapsone | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| debrisoquin | Homo sapiens (human) | IC50 | 951.8000 | 1 | 1 |
| desipramine | Homo sapiens (human) | IC50 | 139.4667 | 3 | 3 |
| diazepam | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| diazoxide | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| dibenzothiophene | Homo sapiens (human) | IC50 | 387.9000 | 1 | 1 |
| dibucaine | Homo sapiens (human) | IC50 | 41.6500 | 1 | 1 |
| diclofenac | Homo sapiens (human) | IC50 | 54.4850 | 2 | 2 |
| dichlorphenamide | Homo sapiens (human) | IC50 | 919.1000 | 1 | 1 |
| dicyclomine | Homo sapiens (human) | IC50 | 40.0400 | 1 | 1 |
| dilacor xr | Homo sapiens (human) | IC50 | 82.0200 | 1 | 1 |
| dimethadione | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| diphenhydramine | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| diphenylpyraline | Homo sapiens (human) | IC50 | 508.8000 | 1 | 1 |
| dipyridamole | Homo sapiens (human) | IC50 | 4.0000 | 1 | 1 |
| disopyramide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| disulfiram | Homo sapiens (human) | IC50 | 71.5000 | 2 | 2 |
| valproic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| domperidone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| donepezil | Homo sapiens (human) | IC50 | 143.1000 | 3 | 3 |
| doxepin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| doxylamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| droperidol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| dyclonine | Homo sapiens (human) | IC50 | 275.4000 | 1 | 1 |
| dyphylline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ebastine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ebselen | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| econazole | Homo sapiens (human) | IC50 | 11.7000 | 2 | 2 |
| enoxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ethacrynic acid | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| profenamine | Homo sapiens (human) | IC50 | 139.2000 | 1 | 1 |
| ethosuximide | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| ethotoin | Homo sapiens (human) | IC50 | 791.9000 | 1 | 1 |
| etidronate | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| brl 42810 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| felbamate | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| 4-biphenylylacetic acid | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| felodipine | Homo sapiens (human) | IC50 | 69.7000 | 1 | 1 |
| fenofibrate | Homo sapiens (human) | IC50 | 23.8667 | 3 | 3 |
| fenoldopam | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| berotek | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| flecainide | Homo sapiens (human) | IC50 | 217.6000 | 1 | 1 |
| fleroxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| fluconazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| flucytosine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| fluphenazine | Homo sapiens (human) | IC50 | 25.8200 | 1 | 1 |
| flumazenil | Homo sapiens (human) | IC50 | 420.3000 | 5 | 5 |
| fluorescite | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| fluorouracil | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| fluoxetine | Homo sapiens (human) | IC50 | 137.2667 | 3 | 3 |
| flurbiprofen | Homo sapiens (human) | IC50 | 724.7000 | 1 | 1 |
| flutamide | Homo sapiens (human) | IC50 | 94.9971 | 7 | 7 |
| furosemide | Homo sapiens (human) | IC50 | 646.5600 | 5 | 5 |
| gabapentin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| gemfibrozil | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| glafenine | Homo sapiens (human) | IC50 | 18.6150 | 2 | 2 |
| gliclazide | Homo sapiens (human) | IC50 | 574.6000 | 3 | 3 |
| glimepiride | Homo sapiens (human) | IC50 | 18.8500 | 4 | 4 |
| glipizide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| glyburide | Homo sapiens (human) | IC50 | 54.9750 | 8 | 8 |
| glyburide | Homo sapiens (human) | Ki | 27.5000 | 1 | 1 |
| guaifenesin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| guanethidine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| guanfacine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| haloperidol | Homo sapiens (human) | IC50 | 96.9200 | 3 | 3 |
| hexoprenaline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| hexamethylene bisacetamide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| hycanthone | Homo sapiens (human) | IC50 | 29.8000 | 1 | 1 |
| hydralazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| hydrochlorothiazide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| hydroflumethiazide | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| hydroxyurea | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| hydroxyzine | Homo sapiens (human) | IC50 | 72.9100 | 1 | 1 |
| ibuprofen | Homo sapiens (human) | IC50 | 507.5333 | 3 | 3 |
| phenelzine | Homo sapiens (human) | IC50 | 897.2000 | 1 | 1 |
| lidocaine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| ifosfamide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| imipramine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| amrinone | Homo sapiens (human) | IC50 | 212.9333 | 3 | 3 |
| indapamide | Homo sapiens (human) | IC50 | 137.5667 | 3 | 3 |
| indomethacin | Homo sapiens (human) | IC50 | 44.4400 | 3 | 3 |
| iodoquinol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| iohexol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| iproniazid | Homo sapiens (human) | IC50 | 555.1500 | 4 | 4 |
| avapro | Homo sapiens (human) | IC50 | 7.3067 | 3 | 3 |
| isoetharine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| isoniazid | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| isoproterenol | Homo sapiens (human) | IC50 | 993.1000 | 2 | 2 |
| isoxsuprine | Homo sapiens (human) | IC50 | 572.5000 | 1 | 1 |
| isradipine | Homo sapiens (human) | IC50 | 28.0000 | 1 | 1 |
| itraconazole | Homo sapiens (human) | IC50 | 18.0000 | 2 | 2 |
| ketamine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| ketanserin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| ketoconazole | Homo sapiens (human) | IC50 | 13.7667 | 6 | 6 |
| ketotifen | Homo sapiens (human) | IC50 | 583.5000 | 2 | 2 |
| labetalol | Homo sapiens (human) | IC50 | 649.1000 | 1 | 1 |
| lamotrigine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| lansoprazole | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| leflunomide | Homo sapiens (human) | IC50 | 140.1333 | 3 | 3 |
| letrozole | Homo sapiens (human) | IC50 | 179.0000 | 2 | 2 |
| lofepramine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| lomustine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| loperamide | Homo sapiens (human) | IC50 | 67.0000 | 1 | 1 |
| loratadine | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| losartan | Homo sapiens (human) | IC50 | 9.0100 | 3 | 3 |
| ly 171883 | Homo sapiens (human) | IC50 | 10.7400 | 1 | 1 |
| maprotiline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| mebendazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| meclofenamic acid | Homo sapiens (human) | IC50 | 27.2400 | 1 | 1 |
| mefenamic acid | Homo sapiens (human) | IC50 | 95.0000 | 2 | 2 |
| memantine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| mephenesin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| mephenytoin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| benzoic acid [2-methyl-2-(propylamino)propyl] ester | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| mesalamine | Homo sapiens (human) | IC50 | 381.0000 | 1 | 1 |
| metaproterenol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| metformin | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| methapyrilene | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| methocarbamol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| metoclopramide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| metoprolol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| metronidazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| metyrapone | Homo sapiens (human) | IC50 | 229.0000 | 1 | 1 |
| mexiletine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mianserin | Homo sapiens (human) | IC50 | 46.8200 | 1 | 1 |
| miconazole | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| midazolam | Homo sapiens (human) | IC50 | 41.7133 | 3 | 3 |
| minoxidil | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| mirtazapine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mitotane | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| moclobemide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| acecainide | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| nadolol | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| nafronyl | Homo sapiens (human) | IC50 | 11.0400 | 1 | 1 |
| naftopidil | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| nalidixic acid | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| naphazoline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| nefazodone | Homo sapiens (human) | IC50 | 6.7350 | 6 | 6 |
| nefopam | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| neostigmine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| nevirapine | Homo sapiens (human) | IC50 | 187.5333 | 3 | 3 |
| nicardipine | Homo sapiens (human) | IC50 | 8.3140 | 5 | 5 |
| nifedipine | Homo sapiens (human) | IC50 | 45.5875 | 4 | 4 |
| nilvadipine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| nimesulide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| nimodipine | Homo sapiens (human) | IC50 | 92.7000 | 3 | 3 |
| nisoldipine | Homo sapiens (human) | IC50 | 33.0000 | 2 | 2 |
| nitrazepam | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| nitrendipine | Homo sapiens (human) | IC50 | 23.7500 | 2 | 2 |
| nitromide | Homo sapiens (human) | IC50 | 184.5000 | 1 | 1 |
| nomifensine | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| norfloxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| nortriptyline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| 6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one | Homo sapiens (human) | IC50 | 23.9100 | 1 | 1 |
| nylidrin | Homo sapiens (human) | IC50 | 280.0000 | 1 | 1 |
| ofloxacin | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| omeprazole | Homo sapiens (human) | IC50 | 87.0000 | 2 | 2 |
| ondansetron | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| orphenadrine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| oxaprozin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| oxethazaine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| oxibendazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| oxprenolol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| benoxinate | Homo sapiens (human) | IC50 | 309.1000 | 1 | 1 |
| oxybutynin | Homo sapiens (human) | IC50 | 27.4000 | 3 | 3 |
| papaverine | Homo sapiens (human) | IC50 | 92.6667 | 3 | 3 |
| pargyline | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| pemoline | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pentamidine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| pentoxifylline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| perhexiline | Homo sapiens (human) | IC50 | 14.3600 | 1 | 1 |
| perphenazine | Homo sapiens (human) | IC50 | 100.9467 | 3 | 3 |
| phenacemide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| phenacetin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| phenobarbital | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| phenoxybenzamine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| 1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| picotamide | Homo sapiens (human) | IC50 | 441.0000 | 1 | 1 |
| pinacidil | Homo sapiens (human) | IC50 | 254.7000 | 2 | 2 |
| pindolol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| pioglitazone | Homo sapiens (human) | IC50 | 0.3370 | 6 | 6 |
| piracetam | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| pirenzepine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| piretanide | Homo sapiens (human) | IC50 | 790.6000 | 1 | 1 |
| piribedil | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| practolol | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| duodote | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ono 1078 | Homo sapiens (human) | IC50 | 2.9700 | 1 | 1 |
| pyranoprofen | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| praziquantel | Homo sapiens (human) | IC50 | 74.7233 | 3 | 3 |
| prazosin | Homo sapiens (human) | IC50 | 146.6000 | 3 | 3 |
| primaquine | Homo sapiens (human) | IC50 | 39.5067 | 3 | 3 |
| primidone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| proadifen | Homo sapiens (human) | IC50 | 13.1900 | 1 | 1 |
| probenecid | Homo sapiens (human) | IC50 | 428.2000 | 3 | 3 |
| probucol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| procainamide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| procaine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| prochlorperazine | Homo sapiens (human) | IC50 | 92.6667 | 3 | 3 |
| procyclidine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| promethazine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| propafenone | Homo sapiens (human) | IC50 | 93.3500 | 2 | 2 |
| propranolol | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| protriptyline | Homo sapiens (human) | IC50 | 128.6000 | 1 | 1 |
| pyrilamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pyrimethamine | Homo sapiens (human) | IC50 | 200.1000 | 1 | 1 |
| ranitidine | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| riluzole | Homo sapiens (human) | IC50 | 136.0000 | 2 | 2 |
| risperidone | Homo sapiens (human) | IC50 | 92.7500 | 3 | 3 |
| rofecoxib | Homo sapiens (human) | IC50 | 121.1200 | 3 | 3 |
| roxarsone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| salicylamide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| salicylsalicylic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfadiazine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| sotalol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| spiperone | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| imatinib | Homo sapiens (human) | IC50 | 21.3250 | 4 | 4 |
| vorinostat | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| succinylsulfathiazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfacetamide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfadimethoxine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfamerazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfamethazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfamethizole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfamethoxazole | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| sulfanitran | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| sulfasalazine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| sulfinpyrazone | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| sulfisoxazole | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| sulpiride | Homo sapiens (human) | IC50 | 638.1000 | 2 | 2 |
| sumatriptan | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| gatifloxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tazarotene | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| telenzepine | Homo sapiens (human) | IC50 | 315.3000 | 1 | 1 |
| temozolomide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| terazosin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| terbutaline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| terfenadine | Homo sapiens (human) | IC50 | 75.2350 | 2 | 2 |
| tetracaine | Homo sapiens (human) | IC50 | 512.9000 | 1 | 1 |
| tetrahydroxy-1,4-quinone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| thalidomide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| thiabendazole | Homo sapiens (human) | IC50 | 560.0000 | 1 | 1 |
| 2-thiosalicylic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| thioridazine | Homo sapiens (human) | IC50 | 24.3300 | 1 | 1 |
| thiotepa | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| tiapride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ticlopidine | Homo sapiens (human) | IC50 | 50.4750 | 2 | 2 |
| tilorone | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| tinidazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tizanidine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| nikethamide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tolazamide | Homo sapiens (human) | IC50 | 285.7000 | 1 | 1 |
| tolazoline | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| tolbutamide | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| tolnaftate | Homo sapiens (human) | IC50 | 71.6600 | 2 | 2 |
| trapidil | Homo sapiens (human) | IC50 | 627.8000 | 1 | 1 |
| trazodone | Homo sapiens (human) | IC50 | 119.3333 | 3 | 3 |
| triamterene | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| trifluoperazine | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| trifluperidol | Homo sapiens (human) | IC50 | 19.7000 | 1 | 1 |
| triflupromazine | Homo sapiens (human) | IC50 | 39.0100 | 1 | 1 |
| trimebutine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| trimeprazine | Homo sapiens (human) | IC50 | 73.7200 | 1 | 1 |
| trimethoprim | Homo sapiens (human) | IC50 | 367.0333 | 3 | 3 |
| trioxsalen | Homo sapiens (human) | IC50 | 525.1000 | 1 | 1 |
| troglitazone | Homo sapiens (human) | IC50 | 13.8143 | 7 | 7 |
| tropicamide | Homo sapiens (human) | IC50 | 150.9000 | 1 | 1 |
| thenoyltrifluoroacetone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tulobuterol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| undecylenic acid | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| urapidil | Homo sapiens (human) | IC50 | 93.1000 | 3 | 3 |
| urethane | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| venlafaxine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| vigabatrin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pirinixic acid | Homo sapiens (human) | IC50 | 87.0000 | 2 | 2 |
| xylazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| xylometazoline | Homo sapiens (human) | IC50 | 796.1000 | 1 | 1 |
| ici 204,219 | Homo sapiens (human) | IC50 | 11.1000 | 2 | 2 |
| zaleplon | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| zonisamide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| zopiclone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| prednisolone | Homo sapiens (human) | IC50 | 119.8233 | 3 | 3 |
| estriol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| reserpine | Homo sapiens (human) | IC50 | 9.0700 | 5 | 5 |
| phentolamine | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| piperonyl butoxide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| penicillamine | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| estrone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| penicillin g | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| metaraminol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pentylenetetrazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| triiodothyronine | Homo sapiens (human) | IC50 | 11.2700 | 1 | 1 |
| carbon tetrachloride | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| chloramphenicol | Homo sapiens (human) | IC50 | 408.6333 | 3 | 3 |
| physostigmine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ethinyl estradiol | Homo sapiens (human) | IC50 | 12.0000 | 2 | 2 |
| tubocurarine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| apomorphine | Homo sapiens (human) | IC50 | 159.8333 | 3 | 3 |
| kanamycin a | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| ethopabate | Homo sapiens (human) | IC50 | 478.5000 | 1 | 1 |
| levodopa | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cysteamine | Homo sapiens (human) | IC50 | 331.0000 | 1 | 1 |
| acepromazine | Homo sapiens (human) | IC50 | 111.6000 | 1 | 1 |
| methoxamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| cloxacillin | Homo sapiens (human) | IC50 | 130.6350 | 2 | 2 |
| zoxazolamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| berlition | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| desoxycorticosterone | Homo sapiens (human) | IC50 | 17.0600 | 1 | 1 |
| colchicine | Homo sapiens (human) | IC50 | 188.9000 | 3 | 3 |
| triamcinolone diacetate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| norethindrone | Homo sapiens (human) | IC50 | 31.7300 | 2 | 2 |
| cycloserine | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| cytarabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| trifluridine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| medroxyprogesterone acetate | Homo sapiens (human) | IC50 | 15.7000 | 1 | 1 |
| triamcinolone acetonide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mepenzolate bromide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pantothenic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulfachlorpyridazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| methylprednisolone | Homo sapiens (human) | IC50 | 100.3433 | 3 | 3 |
| rotenone | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| brompheniramine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| phensuximide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| dimethisoquin | Homo sapiens (human) | IC50 | 68.6800 | 1 | 1 |
| synephrine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pyridostigmine bromide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| benzonatate | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| phenformin | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| framycetin | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| cinchophen | Homo sapiens (human) | IC50 | 754.4000 | 2 | 2 |
| chloroprocaine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| yohimbine | Homo sapiens (human) | IC50 | 254.0000 | 1 | 1 |
| ditiocarb | Homo sapiens (human) | IC50 | 69.2600 | 1 | 1 |
| ethynodiol diacetate | Homo sapiens (human) | IC50 | 62.0000 | 1 | 1 |
| propantheline bromide | Homo sapiens (human) | IC50 | 291.3000 | 1 | 1 |
| aminophylline | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| galantamine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| procarbazine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| betamethasone | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| fluorometholone | Homo sapiens (human) | IC50 | 100.9000 | 1 | 1 |
| chenodeoxycholic acid | Homo sapiens (human) | IC50 | 10.6000 | 1 | 1 |
| glycocholic acid | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| emetine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| dihydralazine | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| dimenhydrinate | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| 4-(benzoylamino)-2-hydroxybenzoic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| 1-naphthylisothiocyanate | Homo sapiens (human) | IC50 | 64.5000 | 2 | 2 |
| megestrol acetate | Homo sapiens (human) | IC50 | 13.9000 | 2 | 2 |
| trimetozine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| glycochenodeoxycholic acid | Homo sapiens (human) | Ki | 7.0000 | 1 | 1 |
| erythromycin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| docosanol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| hydroxychloroquine sulfate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| levonorgestrel | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| vinblastine | Homo sapiens (human) | IC50 | 88.3500 | 2 | 2 |
| ethambutol hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tetramethylpyrazine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| antimycin a | Homo sapiens (human) | IC50 | 52.3000 | 2 | 2 |
| pregnenolone carbonitrile | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| flurandrenolone | Homo sapiens (human) | IC50 | 71.1900 | 1 | 1 |
| metylperon | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| amiloride | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pimozide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| flumethasone | Homo sapiens (human) | IC50 | 68.4600 | 1 | 1 |
| sulfadoxine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| stavudine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| dicloxacillin | Homo sapiens (human) | IC50 | 45.2750 | 4 | 4 |
| tranylcypromine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| streptomycin | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| cladribine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| beclomethasone | Homo sapiens (human) | IC50 | 16.9850 | 2 | 2 |
| metocurine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| floxacillin | Homo sapiens (human) | IC50 | 109.3000 | 2 | 2 |
| etidronate disodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| zalcitabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| camptothecin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| mafenide acetate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| (1S,2R)-tranylcypromine | Homo sapiens (human) | IC50 | 102.7000 | 1 | 1 |
| diacerein | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| parbendazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| selegiline hydrochloride, (r)-isomer | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| levamisole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| thiamphenicol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pancuronium bromide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ornidazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| danazol | Homo sapiens (human) | IC50 | 15.8000 | 3 | 3 |
| metergoline | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| fenclozic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| capobenic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| diftalone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| fludarabine phosphate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| carbimazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ursodeoxycholic acid | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| benzonidazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rose bengal b disodium salt | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| clobetasol propionate | Homo sapiens (human) | IC50 | 8.5000 | 2 | 2 |
| amoxicillin | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| timolol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| indoramin | Homo sapiens (human) | IC50 | 125.6667 | 3 | 3 |
| oxcarbazepine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| carbidopa | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| zidovudine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| feprazone | Homo sapiens (human) | IC50 | 73.9000 | 1 | 1 |
| tobramycin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| paclitaxel | Homo sapiens (human) | IC50 | 22.0200 | 5 | 5 |
| etoposide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| dobutamine | Homo sapiens (human) | IC50 | 550.0000 | 2 | 2 |
| ribavirin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| amikacin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| methyldopa | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| bezafibrate | Homo sapiens (human) | IC50 | 206.2500 | 2 | 2 |
| diltiazem | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| vecuronium bromide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| benoxaprofen | Homo sapiens (human) | IC50 | 139.3500 | 2 | 2 |
| nitazoxanide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| acarbose | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| torsemide | Homo sapiens (human) | IC50 | 130.7000 | 1 | 1 |
| lorcainide | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| piperacillin | Homo sapiens (human) | IC50 | 197.4000 | 1 | 1 |
| captopril | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| staurosporine | Homo sapiens (human) | IC50 | 18.7000 | 2 | 2 |
| foscarnet sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| indalpine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| atracurium besylate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| lidamidine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| nicorandil | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pergolide mesylate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cefadroxil anhydrous | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| talniflumate | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| fenoldopam mesylate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| nedocromil | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| fialuridine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| cefaclor anhydrous | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pefloxacin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| alfentanil | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| dazoxiben | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| cefotetan | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| lovastatin | Homo sapiens (human) | IC50 | 19.3000 | 2 | 2 |
| flupirtine | Homo sapiens (human) | IC50 | 35.5000 | 2 | 2 |
| tolrestat | Homo sapiens (human) | IC50 | 185.3000 | 1 | 1 |
| enoximone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| stepronin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| simvastatin | Homo sapiens (human) | IC50 | 21.0250 | 4 | 4 |
| idazoxan | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| remoxipride | Homo sapiens (human) | IC50 | 92.6667 | 3 | 3 |
| cabergoline | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| atomoxetine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| quinapril | Homo sapiens (human) | IC50 | 54.7500 | 2 | 2 |
| alpidem | Homo sapiens (human) | IC50 | 9.1887 | 4 | 4 |
| mifepristone | Homo sapiens (human) | IC50 | 2.0200 | 1 | 1 |
| dopexamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| lonapalene | Homo sapiens (human) | IC50 | 14.3900 | 1 | 1 |
| salmeterol xinafoate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ipsapirone | Homo sapiens (human) | IC50 | 31.1700 | 1 | 1 |
| finasteride | Homo sapiens (human) | IC50 | 28.2000 | 3 | 3 |
| imiquimod | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| sematilide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sertindole | Homo sapiens (human) | IC50 | 82.7000 | 1 | 1 |
| adapalene | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| aromasil | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| sparfloxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| zileuton | Homo sapiens (human) | IC50 | 628.0667 | 3 | 3 |
| remacemide | Homo sapiens (human) | IC50 | 288.1000 | 1 | 1 |
| cidofovir anhydrous | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mibefradil | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| bromfenac | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| gemcitabine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| aripiprazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| atorvastatin calcium anhydrous | Homo sapiens (human) | IC50 | 13.0000 | 1 | 1 |
| lamivudine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| duloxetine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| valsartan | Homo sapiens (human) | IC50 | 82.0350 | 2 | 2 |
| zolmitriptan | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| adefovir dipivoxil | Homo sapiens (human) | IC50 | 46.0000 | 1 | 1 |
| emtricitabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| paroxetine hydrochloride | Homo sapiens (human) | IC50 | 100.9550 | 2 | 2 |
| bupropion hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| trazodone hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| verapamil hydrochloride | Homo sapiens (human) | IC50 | 20.5000 | 1 | 1 |
| doxazosin mesylate | Homo sapiens (human) | IC50 | 45.0000 | 1 | 1 |
| efavirenz | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| nelfinavir | Homo sapiens (human) | IC50 | 11.8000 | 3 | 3 |
| mevastatin | Homo sapiens (human) | IC50 | 27.0000 | 1 | 1 |
| bupivacaine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| plerixafor | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| amprenavir | Homo sapiens (human) | IC50 | 38.2000 | 3 | 3 |
| epigallocatechin gallate | Homo sapiens (human) | IC50 | 214.0000 | 1 | 1 |
| ticlopidine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| epirubicin hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| fenclofenac | Homo sapiens (human) | IC50 | 235.7000 | 1 | 1 |
| proxicromil | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| torbafylline | Homo sapiens (human) | IC50 | 304.9000 | 1 | 1 |
| pazufloxacin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| repaglinide | Homo sapiens (human) | IC50 | 22.0000 | 1 | 1 |
| telmisartan | Homo sapiens (human) | IC50 | 16.2000 | 3 | 3 |
| miconazole nitrate | Homo sapiens (human) | IC50 | 114.0000 | 1 | 1 |
| sertraline | Homo sapiens (human) | IC50 | 29.3400 | 1 | 1 |
| zoledronic acid | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| artemisinin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| brinzolamide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| drospirenone | Homo sapiens (human) | IC50 | 16.4000 | 1 | 1 |
| artemether | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| enrofloxacin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| uk 68798 | Homo sapiens (human) | IC50 | 420.7000 | 2 | 2 |
| hp 873 | Homo sapiens (human) | IC50 | 23.4000 | 1 | 1 |
| loxapine succinate | Homo sapiens (human) | IC50 | 77.0000 | 1 | 1 |
| voriconazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| betamipron | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| mepindolol | Homo sapiens (human) | IC50 | 35.8700 | 1 | 1 |
| fpl 52791 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| uroxatral | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| aceclofenac | Homo sapiens (human) | IC50 | 105.0000 | 1 | 1 |
| epanolol | Homo sapiens (human) | IC50 | 244.4000 | 1 | 1 |
| thiocolchicoside | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| methotrimeprazine | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
| doripenem | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rosiglitazone | Homo sapiens (human) | IC50 | 4.5853 | 6 | 6 |
| tamiflu | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bexarotene | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| s20098 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| flunisolide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ketorolac tromethamine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| clarithromycin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| nicotine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| gliquidone | Homo sapiens (human) | IC50 | 11.6000 | 1 | 1 |
| lopinavir | Homo sapiens (human) | IC50 | 17.3000 | 2 | 2 |
| levcromakalim | Homo sapiens (human) | IC50 | 353.3000 | 1 | 1 |
| moxifloxacin hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| hexylcaine hydrochloride | Homo sapiens (human) | IC50 | 505.7000 | 1 | 1 |
| fulvestrant | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mizoribine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| imipenem, anhydrous | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sr141716 | Homo sapiens (human) | IC50 | 17.5000 | 2 | 2 |
| bosentan anhydrous | Homo sapiens (human) | IC50 | 27.4800 | 5 | 5 |
| fpl 55712 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sivelestat | Homo sapiens (human) | IC50 | 142.2000 | 1 | 1 |
| racecadotril | Homo sapiens (human) | IC50 | 20.3000 | 1 | 1 |
| tadalafil | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| plavix | Homo sapiens (human) | IC50 | 72.0000 | 1 | 1 |
| clofarabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pramipexole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| valdecoxib | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| fpl-52694 | Homo sapiens (human) | IC50 | 270.6000 | 1 | 1 |
| mk 0663 | Homo sapiens (human) | IC50 | 49.1000 | 2 | 2 |
| gefitinib | Homo sapiens (human) | IC50 | 10.9000 | 3 | 3 |
| ramatroban | Homo sapiens (human) | IC50 | 62.4000 | 1 | 1 |
| desloratadine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| methotrexate | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| xaliproden | Homo sapiens (human) | IC50 | 117.1000 | 1 | 1 |
| n-isobutyrylcysteine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sulbactam | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| olmesartan medoxomil | Homo sapiens (human) | IC50 | 4.7300 | 1 | 1 |
| dexpanthenol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| quilostigmine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| abiraterone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| imiloxan | Homo sapiens (human) | IC50 | 61.6500 | 1 | 1 |
| febuxostat | Homo sapiens (human) | IC50 | 42.9000 | 1 | 1 |
| aspartame | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| tempol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| lexapro | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| docetaxel anhydrous | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| levofloxacin | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| ezetimibe | Homo sapiens (human) | IC50 | 56.0000 | 1 | 1 |
| cox 189 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| vatalanib | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| moxifloxacin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| clevidipine | Homo sapiens (human) | IC50 | 36.3500 | 1 | 1 |
| hyoscyamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| xamoterol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| naproxen | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| lactitol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| telbivudine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| fpl 52757 | Homo sapiens (human) | IC50 | 111.7000 | 1 | 1 |
| paromomycin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| fpl 59257 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| atropine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| ropivacaine | Homo sapiens (human) | IC50 | 646.4000 | 1 | 1 |
| erlotinib | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| zeneca zd 6169 | Homo sapiens (human) | IC50 | 21.3900 | 1 | 1 |
| sibenadet | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| latrepirdine | Homo sapiens (human) | IC50 | 135.9000 | 1 | 1 |
| ramelteon | Homo sapiens (human) | IC50 | 109.0000 | 2 | 2 |
| lapatinib | Homo sapiens (human) | IC50 | 7.3750 | 4 | 4 |
| deferasirox | Homo sapiens (human) | IC50 | 58.4000 | 1 | 1 |
| bms204352 | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| tbc-11251 | Homo sapiens (human) | IC50 | 12.6000 | 1 | 1 |
| tolvaptan | Homo sapiens (human) | IC50 | 9.9900 | 1 | 1 |
| sorafenib | Homo sapiens (human) | IC50 | 8.6667 | 3 | 3 |
| lenalidomide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| lacosamide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cortisone | Homo sapiens (human) | IC50 | 108.1000 | 1 | 1 |
| vincaleukoblastine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| vincristine sulfate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| phenethicillin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| wortmannin | Homo sapiens (human) | IC50 | 13.6000 | 2 | 2 |
| taurochenodeoxycholic acid | Homo sapiens (human) | Ki | 28.0000 | 1 | 1 |
| bortezomib | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ritonavir | Homo sapiens (human) | IC50 | 2.0850 | 4 | 4 |
| ouabain | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| salicin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pentostatin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| taurolithocholic acid | Homo sapiens (human) | IC50 | 189.2000 | 1 | 1 |
| quinidine | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| meropenem | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| digitoxin | Homo sapiens (human) | IC50 | 20.5000 | 2 | 2 |
| saquinavir | Homo sapiens (human) | IC50 | 3.9000 | 4 | 4 |
| perindopril erbumine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| miglitol | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rocuronium bromide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| erythromycin estolate | Homo sapiens (human) | IC50 | 10.0333 | 3 | 3 |
| linezolid | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| (S)-bicalutamide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| devazepide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pemirolast potassium salt | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| eplerenone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| halcinonide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| metrizamide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| ao 128 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| loteprednol etabonate | Homo sapiens (human) | IC50 | 40.4000 | 1 | 1 |
| fluticasone propionate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tretinoin | Homo sapiens (human) | IC50 | 71.5000 | 2 | 2 |
| tacrolimus | Homo sapiens (human) | IC50 | 7.1800 | 1 | 1 |
| mupirocin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| zithromax | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| decitabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| teniposide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| valrubicin | Homo sapiens (human) | IC50 | 24.1000 | 1 | 1 |
| ketoconazole | Homo sapiens (human) | IC50 | 3.4000 | 1 | 1 |
| melphalan | Homo sapiens (human) | IC50 | 113.3750 | 2 | 2 |
| posaconazole | Homo sapiens (human) | IC50 | 8.1000 | 1 | 1 |
| rubitecan | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| arginine vasopressin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| trilostane | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| leuprolide acetate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| propylthiouracil | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| chlorprothixene | Homo sapiens (human) | IC50 | 27.4700 | 1 | 1 |
| etomidate | Homo sapiens (human) | IC50 | 61.6100 | 1 | 1 |
| mercaptopurine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| methylthiouracil | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| crotamiton | Homo sapiens (human) | IC50 | 109.5000 | 1 | 1 |
| levosulpiride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| flunarizine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| thiothixene | Homo sapiens (human) | IC50 | 30.4000 | 1 | 1 |
| eszopiclone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| benztropine | Homo sapiens (human) | IC50 | 188.6000 | 1 | 1 |
| methimazole | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| cinnarizine | Homo sapiens (human) | IC50 | 15.7000 | 2 | 2 |
| sulindac | Homo sapiens (human) | IC50 | 139.4225 | 4 | 4 |
| capsaicin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| epalrestat | Homo sapiens (human) | IC50 | 36.8000 | 1 | 1 |
| drotaverin | Homo sapiens (human) | IC50 | 37.0000 | 2 | 2 |
| digoxin | Homo sapiens (human) | IC50 | 264.1000 | 1 | 1 |
| tamoxifen | Homo sapiens (human) | IC50 | 63.3400 | 5 | 5 |
| ethionamide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| fusidic acid | Homo sapiens (human) | IC50 | 10.5667 | 3 | 3 |
| scopolamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| valinomycin | Homo sapiens (human) | IC50 | 3.4533 | 3 | 3 |
| ranitidine | Homo sapiens (human) | IC50 | 567.5000 | 2 | 2 |
| hmr 3647 | Homo sapiens (human) | IC50 | 13.0000 | 3 | 3 |
| latoconazole | Homo sapiens (human) | IC50 | 9.6500 | 1 | 1 |
| maraviroc | Homo sapiens (human) | IC50 | 110.0000 | 1 | 1 |
| toremifene citrate | Homo sapiens (human) | IC50 | 115.0000 | 1 | 1 |
| nelarabine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| almokalant | Homo sapiens (human) | IC50 | 55.7500 | 1 | 1 |
| gestodene | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| orlistat | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| quinine | Homo sapiens (human) | IC50 | 122.2767 | 3 | 3 |
| vx-745 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| azilect | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| deracoxib | Homo sapiens (human) | IC50 | 20.1800 | 1 | 1 |
| dasatinib | Homo sapiens (human) | IC50 | 11.5500 | 2 | 2 |
| 2-aminohippuric acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| rs-130830 | Homo sapiens (human) | IC50 | 23.3600 | 1 | 1 |
| sitagliptin | Homo sapiens (human) | IC50 | 138.5000 | 3 | 3 |
| tolcapone | Homo sapiens (human) | IC50 | 56.1550 | 4 | 4 |
| quercetin | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| dinoprostone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| calcitriol | Homo sapiens (human) | IC50 | 39.7000 | 1 | 1 |
| vitamin k semiquinone radical | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| beta carotene | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| alprostadil | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| vitamin d 2 | Homo sapiens (human) | IC50 | 75.8000 | 1 | 1 |
| clavulanic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| pulmicort | Homo sapiens (human) | IC50 | 46.0000 | 1 | 1 |
| oxymetholone | Homo sapiens (human) | IC50 | 48.7000 | 1 | 1 |
| eprosartan | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| brompheniramine maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| dexchlorpheniramine maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mycophenolate mofetil | Homo sapiens (human) | IC50 | 76.0000 | 1 | 1 |
| entacapone | Homo sapiens (human) | IC50 | 55.6000 | 1 | 1 |
| l 660,711 | Homo sapiens (human) | IC50 | 3.5150 | 2 | 2 |
| pheniramine maleate | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| travoprost | Homo sapiens (human) | IC50 | 43.9000 | 1 | 1 |
| tranilast | Homo sapiens (human) | IC50 | 41.5000 | 1 | 1 |
| imipenem | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| etretinate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| isotretinoin | Homo sapiens (human) | IC50 | 37.1000 | 2 | 2 |
| ketotifen fumarate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| dinoprost tromethamine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| triprolidine | Homo sapiens (human) | IC50 | 290.8000 | 1 | 1 |
| rosuvastatin calcium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| terbinafine hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| homatropine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| cyclosporine | Homo sapiens (human) | IC50 | 3.5000 | 8 | 8 |
| cyclosporine | Homo sapiens (human) | Ki | 9.5000 | 1 | 1 |
| natamycin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| acitretin | Homo sapiens (human) | IC50 | 28.2000 | 2 | 2 |
| levetiracetam | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| nalmefene | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| naloxone | Homo sapiens (human) | IC50 | 272.3333 | 3 | 3 |
| sirolimus | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| topiramate | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| morphine | Homo sapiens (human) | IC50 | 135.0000 | 1 | 1 |
| demycarosylturimycin h | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ar c67085mx | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| acipimox | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| atosiban | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bimatoprost | Homo sapiens (human) | IC50 | 40.4000 | 1 | 1 |
| desoximetasone | Homo sapiens (human) | IC50 | 16.4200 | 1 | 1 |
| latanoprost | Homo sapiens (human) | IC50 | 12.9000 | 1 | 1 |
| nateglinide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| sb 223412 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| su 11248 | Homo sapiens (human) | IC50 | 45.8100 | 1 | 1 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | Homo sapiens (human) | IC50 | 36.1000 | 3 | 3 |
| molsidomine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| naltrexone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| butorphanol | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| cefixime | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| lisinopril | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ramipril | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| indinavir sulfate | Homo sapiens (human) | IC50 | 21.2000 | 3 | 3 |
| zimeldine | Homo sapiens (human) | IC50 | 229.7000 | 1 | 1 |
| enalapril maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| enalaprilat anhydrous | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| trandolapril | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| pregabalin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tiotropium | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| alvimopan anhydrous | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| guanabenz | Homo sapiens (human) | IC50 | 343.7000 | 1 | 1 |
| famotidine | Homo sapiens (human) | IC50 | 422.6667 | 3 | 3 |
| nw 1029 | Homo sapiens (human) | IC50 | 174.7000 | 1 | 1 |
| cci 15641 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rifamycin sv | Homo sapiens (human) | IC50 | 58.6250 | 4 | 4 |
| rifamycin sv | Homo sapiens (human) | Ki | 31.0000 | 1 | 1 |
| tenofovir disoproxil fumarate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| dexbrompheniramine maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rifaximin | Homo sapiens (human) | IC50 | 42.0000 | 1 | 1 |
| ici d1542 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| everolimus | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| gavestinel | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| cefpodoxime proxetil | Homo sapiens (human) | IC50 | 81.7000 | 1 | 1 |
| 1-methyl-d-lysergic acid butanolamide | Homo sapiens (human) | IC50 | 33.0700 | 1 | 1 |
| fluphenazine | Homo sapiens (human) | IC50 | 87.3000 | 1 | 1 |
| nitrofurantoin | Homo sapiens (human) | IC50 | 711.0000 | 3 | 3 |
| dantrolene | Homo sapiens (human) | IC50 | 145.5000 | 1 | 1 |
| roxithromycin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cefdinir | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bisoprolol, fumarate (1:1) salt | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| artesunate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tipredane | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| etoposide phosphate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ciclesonide | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| temsirolimus | Homo sapiens (human) | IC50 | 2.6900 | 1 | 1 |
| dutasteride | Homo sapiens (human) | IC50 | 29.8000 | 1 | 1 |
| tekturna | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| vildagliptin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| bentiromide | Homo sapiens (human) | IC50 | 234.8000 | 1 | 1 |
| sgd 301-76 | Homo sapiens (human) | IC50 | 49.3000 | 1 | 1 |
| fluvoxamine maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| thioacetazone | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| gemifloxacin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| dexlansoprazole | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| gemifloxacin mesylate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| utibapril | Homo sapiens (human) | IC50 | 13.5100 | 1 | 1 |
| etomoxir | Homo sapiens (human) | IC50 | 11.8000 | 1 | 1 |
| zd 9379 | Homo sapiens (human) | IC50 | 490.0000 | 1 | 1 |
| ly 450139 | Homo sapiens (human) | IC50 | 471.9000 | 1 | 1 |
| cangrelor | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| sch 527123 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| rivaroxaban | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| hki 272 | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| tofacitinib | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| linaprazan | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pazopanib | Homo sapiens (human) | IC50 | 10.3000 | 1 | 1 |
| lecozotan | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| ar c155858 | Homo sapiens (human) | IC50 | 247.8000 | 1 | 1 |
| amg 009 | Homo sapiens (human) | IC50 | 11.5000 | 1 | 1 |
| cefotaxime sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | Homo sapiens (human) | IC50 | 196.6000 | 1 | 1 |
| alisporivir | Homo sapiens (human) | IC50 | 0.1100 | 1 | 1 |
| losartan potassium | Homo sapiens (human) | IC50 | 8.5300 | 1 | 1 |
| scopolamine hydrobromide | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| dactolisib | Homo sapiens (human) | IC50 | 7.9000 | 1 | 1 |
| rabeprazole sodium | Homo sapiens (human) | IC50 | 33.9000 | 1 | 1 |
| bivalirudin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| somatostatin | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ly-146032 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| warfarin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| azd 7545 | Homo sapiens (human) | IC50 | 12.8500 | 1 | 1 |
| pravastatin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| alendronate sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| sl 80.0750 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mesna | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| clavulanate potassium | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| cytomel | Homo sapiens (human) | IC50 | 11.2700 | 1 | 1 |
| piperacillin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| oxacillin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| cefazolin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| azlocillin sodium | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| a 967079 | Homo sapiens (human) | IC50 | 26.8100 | 1 | 1 |
| pht 427 | Homo sapiens (human) | IC50 | 21.0400 | 1 | 1 |
| pf 3644022 | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| tetracycline | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| dicumarol | Homo sapiens (human) | IC50 | 39.9300 | 1 | 1 |
| piroxicam | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| roquinimex | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| mobic | Homo sapiens (human) | IC50 | 77.5000 | 1 | 1 |
| mobiflex | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| isoxicam | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| warfarin | Homo sapiens (human) | IC50 | 115.3000 | 1 | 1 |
| minocycline hydrochloride | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tigecycline | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| lornoxicam | Homo sapiens (human) | IC50 | 7.5600 | 1 | 1 |
| entecavir | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| acyclovir | Homo sapiens (human) | IC50 | 567.0000 | 4 | 4 |
| folic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 2 | 2 |
| rifampin | Homo sapiens (human) | IC50 | 20.1500 | 4 | 4 |
| clozapine | Homo sapiens (human) | IC50 | 117.3100 | 4 | 4 |
| dacarbazine | Homo sapiens (human) | IC50 | 566.5000 | 2 | 2 |
| didanosine | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| ganciclovir | Homo sapiens (human) | IC50 | 134.0000 | 2 | 2 |
| valtrex | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| sildenafil | Homo sapiens (human) | IC50 | 16.4300 | 1 | 1 |
| olanzapine | Homo sapiens (human) | IC50 | 93.7850 | 2 | 2 |
| raltitrexed | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| allopurinol | Homo sapiens (human) | IC50 | 116.5000 | 2 | 2 |
| citrovorum factor | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| leucovorin | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| rifapentine | Homo sapiens (human) | IC50 | 9.9100 | 1 | 1 |
| sildenafil citrate | Homo sapiens (human) | IC50 | 132.0000 | 1 | 1 |
| aprepitant | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| tegaserod maleate | Homo sapiens (human) | IC50 | 133.0000 | 1 | 1 |
| rifabutin | Homo sapiens (human) | IC50 | 26.7000 | 3 | 3 |
| carbadox | Homo sapiens (human) | IC50 | 939.8000 | 1 | 1 |
| fenobam | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
Drugs with Other Measurements
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.Gastroenterology, , Volume: 123, Issue:5, 2002
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.Journal of medicinal chemistry, , 10-22, Volume: 63, Issue:20, 2020
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.Gastroenterology, , Volume: 123, Issue:5, 2002
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.Pharmaceutical research, , Volume: 20, Issue:4, 2003
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.Gastroenterology, , Volume: 123, Issue:5, 2002
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:1, 2012
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.Hepatology (Baltimore, Md.), , Volume: 60, Issue:3, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010
Enables
This protein enables 8 target(s):
| Target | Category | Definition |
|---|
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| ATP binding | molecular function | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. [ISBN:0198506732] |
| ABC-type xenobiotic transporter activity | molecular function | Catalysis of the reaction: ATP + H2O + xenobiotic(in) = ADP + phosphate + xenobiotic(out). [EC:7.6.2.2] |
| bile acid transmembrane transporter activity | molecular function | Enables the transfer of bile acid from one side of a membrane to the other. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. [GOC:ai] |
| canalicular bile acid transmembrane transporter activity | molecular function | The directed movement of bile acid and bile salts out of a hepatocyte and into the bile canaliculus by means of an agent such as a transporter or pore. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. [GOC:dph] |
| carbohydrate transmembrane transporter activity | molecular function | Enables the transfer of carbohydrate from one side of a membrane to the other. [GOC:jl, GOC:mtg_transport, ISBN:0815340729] |
| ABC-type bile acid transporter activity | molecular function | Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: bile acid(in) + ATP + H2O -> bile acid(out) + ADP + phosphate. [RHEA:50048] |
| ATP hydrolysis activity | molecular function | Catalysis of the reaction: ATP + H2O = ADP + H+ phosphate. ATP hydrolysis is used in some reactions as an energy source, for example to catalyze a reaction or drive transport against a concentration gradient. [RHEA:13065] |
Located In
This protein is located in 10 target(s):
| Target | Category | Definition |
|---|
| Golgi membrane | cellular component | The lipid bilayer surrounding any of the compartments of the Golgi apparatus. [GOC:mah] |
| endosome | cellular component | A vacuole to which materials ingested by endocytosis are delivered. [ISBN:0198506732, PMID:19696797] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
| apical plasma membrane | cellular component | The region of the plasma membrane located at the apical end of the cell. [GOC:curators] |
| intercellular canaliculus | cellular component | An extremely narrow tubular channel located between adjacent cells. An instance of this is the secretory canaliculi occurring between adjacent parietal cells in the gastric mucosa of vertebrates. [ISBN:0721662544] |
| intracellular canaliculus | cellular component | An apical plasma membrane part that forms a narrow enfolded luminal membrane channel, lined with numerous microvilli, that appears to extend into the cytoplasm of the cell. A specialized network of intracellular canaliculi is a characteristic feature of parietal cells of the gastric mucosa in vertebrates. [GOC:mah, ISBN:0721662544, PMID:10700045] |
| recycling endosome | cellular component | An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane. [GOC:dph, GOC:jid, GOC:kmv, GOC:rph, PMID:10930469, PMID:15601896, PMID:16246101, PMID:21556374, PMID:21562044] |
| recycling endosome membrane | cellular component | The lipid bilayer surrounding a recycling endosome. [GOC:jid, GOC:rph, PMID:10930469, PMID:15601896, PMID:16246101] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
Involved In
This protein is involved in 22 target(s):
| Target | Category | Definition |
|---|
| fatty acid metabolic process | biological process | The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis. [ISBN:0198547684] |
| bile acid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile. [GOC:go_curators] |
| xenobiotic metabolic process | biological process | The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:cab2, GOC:krc] |
| xenobiotic transmembrane transport | biological process | The process in which a xenobiotic, a compound foreign to the organim exposed to it, is transported across a membrane. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:ai, GOC:bf, GOC:krc] |
| response to oxidative stress | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals. [GOC:jl, PMID:12115731] |
| bile acid metabolic process | biological process | The chemical reactions and pathways involving bile acids, a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. [GOC:go_curators] |
| response to organic cyclic compound | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus. [GOC:ef] |
| bile acid and bile salt transport | biological process | The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:dph, GOC:krc, PMID:12663868, PMID:14699511] |
| canalicular bile acid transport | biological process | Enables the transfer of bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. [GOC:dph] |
| protein ubiquitination | biological process | The process in which one or more ubiquitin groups are added to a protein. [GOC:ai] |
| regulation of fatty acid beta-oxidation | biological process | Any process that modulates the frequency, rate or extent of fatty acid bbeta-oxidation. [GOC:mah] |
| carbohydrate transmembrane transport | biological process | The process in which a carbohydrate is transported across a membrane. [GOC:mah] |
| bile acid signaling pathway | biological process | The series of molecular signals initiated by bile acid binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:bf, GOC:signaling, PMID:12016314] |
| cholesterol homeostasis | biological process | Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell. [GOC:go_curators] |
| response to estrogen | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics. [GOC:jl, ISBN:0198506732] |
| response to ethanol | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. [GOC:go_curators] |
| xenobiotic export from cell | biological process | The directed movement of a xenobiotic from a cell, into the extracellular region. A xenobiotic is a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:go_curators, GOC:krc] |
| lipid homeostasis | biological process | Any process involved in the maintenance of an internal steady state of lipid within an organism or cell. [GOC:BHF, GOC:rl] |
| phospholipid homeostasis | biological process | Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell. [GOC:BHF, GOC:rl] |
| positive regulation of bile acid secretion | biological process | Any process that activates or increases the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue. [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:22767443] |
| regulation of bile acid metabolic process | biological process | Any process that modulates the frequency, rate or extent of bile acid metabolic process. [GO_REF:0000058, GOC:bf, GOC:TermGenie] |
| transmembrane transport | biological process | The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other. [GOC:dph, GOC:jid] |